After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The market continues to defy those players who believe we are seeing the calm before the storm.
The FDA approved Merck's Keytruda, a drug to treat metastatic and recurrent cancer.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.